# Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL

> **NCT00520208** · PHASE2 · COMPLETED · sponsor: **CytRx** · enrollment: 15 (actual)

## Conditions studied

- Acute Promyelocytic Leukemia

## Interventions

- **DRUG:** Tamibarotene

## Key facts

- **NCT ID:** NCT00520208
- **Lead sponsor:** CytRx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2012-12
- **Final completion:** 2013-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2013-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00520208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00520208, "Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00520208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*